In a balanced move aimed at strengthening drug quality while supporting industry practicality, the Drugs Technical Advisory Board (DTAB) has taken key decisions regarding the implementation of the revised Schedule M during its 93rd meeting.
Stricter Microbial Limits Aligned with Global Standards
Under Part (A) of the agenda, the Board reviewed a proposal to revise microbial contamination limits for “Grade A” manufacturing areas. After considering recommendations from the Drugs Consultative Committee (DCC), DTAB approved the amendment to align Indian standards with the globally recognized World Health Organization (WHO) Technical Report Series (TRS) 1044, Annexure II.
This decision is expected to enhance the quality and sterility assurance of pharmaceutical products manufactured in highly controlled environments, bringing India’s regulatory framework closer to international benchmarks.
Relief for Select Drug Categories
In Part (B), DTAB addressed industry concerns regarding the applicability of revised Schedule M requirements to certain product categories. Stakeholders had requested the continuation of earlier exemptions that existed prior to the amendment notified under G.S.R. 922(E) dated December 28, 2023.
After detailed deliberation, the Board acknowledged that some provisions of the revised Schedule M may not be relevant for specific categories such as medical gases, empty gelatin capsules, and disinfectant fluids.
Taking a pragmatic approach, DTAB recommended continuing the exemptions that were available under the earlier version of Schedule M for these categories. This move is expected to reduce unnecessary compliance burdens while ensuring that regulatory focus remains on areas critical to drug safety and quality.
A Balanced Regulatory Approach
The latest decisions reflect DTAB’s intent to strike a balance between adopting stringent global quality standards and addressing practical challenges faced by the pharmaceutical industry. While stricter microbial limits will improve product safety, targeted exemptions will help avoid over-regulation in low-risk segments.
These updates under revised Schedule M are likely to have a significant impact on manufacturing practices across India’s pharmaceutical sector in the coming months.
